Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | RORC | P51449 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | MAP2 | P11137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752748 | 0.91 | CTSA (0.38) | RORCCTSA | |
| SCHEMBL3757232 | 0.83 | ALDH1A1 (0.42) | MAPK10SCN9AKDM4EALDH1A1HPGD | |
| SCHEMBL3747394 | 0.82 | KMO (0.39) | RORCHPGDLMNACTSA | |
| SCHEMBL3749684 | 0.82 | ALDH1A1 (0.41) | MAPK10SCN9ARORCKDM4EALDH1A1 | |
| SCHEMBL3747109 | 0.81 | KDM4E (0.40) | MAPK10SCN9ARORCKDM4EALDH1A1 | |
| SCHEMBL8202544 | 0.79 | ALDH1A1 (0.35) | SCN9ARORCALDH1A1HPGDLMNA | |
| SCHEMBL3752343 | 0.79 | GPBAR1 (0.36) | MAPK10SCN9ARORCKDM4EALDH1A1 | |
| SCHEMBL3755130 | 0.74 | KMO (0.44) | KDM4EALDH1A1HPGDCTSA | |
| SCHEMBL3754265 | 0.73 | ALDH1A1 (0.42) | RORCKDM4EALDH1A1HPGDRORB | |
| SCHEMBL3752534 | 0.72 | ALDH1A1 (0.41) | SCN9AALDH1A1CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | MAPK10 1123/4885SCN9A 2416/4885RORC 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.